The aim of this project is to implement the Tumor-First workflow at a Dutch national level.

The Tumor-First workflow involves testing of tumor tissue of all newly diagnosed epithelial ovarian cancer patients for the presence of pathogenic variants in ovarian cancer risk genes (e.g. BRCA). The tumor DNA test provides information on the effectiveness of treatment with PARP-inhibitors and it functions as a prescreen for germline testing. National implementation will ensure equality in the genetic testing workflows for epithelial ovarian cancer patients in the Netherlands.  

This website has been developed to aid implementation of the Tumor-First workflow. It provides helpful material for clinicians involved in the diagnostic workflow. Most of these materials have been developed in Dutch, however we have translated the most important documents and created an English Toolbox.